Pfizer holding on tight to supplies of COVID-19 drug Paxlovid, limiting the prospect of combination research: report How Amgen and AstraZeneca's asthma drug Tezspire holds promise for colorectal cancer Cerebral CEO Kyle Robertson steps down amid DOJ investigation into prescribing practices Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce NIH scientists use machine learning AI to narrow down risk factors for long COVID 'Startup like no other': China's Hengrui launches Luzsana with Big Pharma veterans at the top and a goal to improve drug access 'We just don’t have the studies': New report details critical diversity shortcomings in US clinical research Humana, private equity firm launch 2nd primary care joint venture C2N launches tau-tallying Alzheimer's blood test to join its amyloid-based screening tool Novo Nordisk's latest obesity awareness campaign has patients stress the need to 'share the weight' Flagship Pioneering unfurls cell signaling company Sonata Therapeutics Roche, bluebird bio settle gene therapy trademark suit around ‘spark’ sickle cell disease campaign J&J’s DePuy Synthes scores FDA clearance in reverse shoulder joint replacements RWJBarnabas Health, Saint Peter's integration deal wins NJ approval, awaits FTC signoff Featured Story | By Zoey Becker Pfizer is keeping a tight fist around supplies of its blockbuster COVID-19 drug, Bloomberg reports. Researchers aren't able to get their hands on the pills for combination studies, which they say could help them fight the looming problem of drug resistance. read more |
| |
|---|
|
Top Stories By Angus Liu Scientists have linked chronic inflammation and regulatory T cells together in pinpointing a potential new drug target for colorectal cancer. The findings point to drugs like Amgen and AstraZeneca's newly approved tezepelumab as a possible treatment for the disease. read more By Heather Landi Kyle Robertson, a co-founder of embattled startup Cerebral, has stepped down from the CEO role, effective immediately, the company announced Wednesday. read more By Max Bayer Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. read more By Andrea Park While it may seem that there’s no clear rhyme or reason to long COVID diagnoses, researchers from the National Institutes of Health are determined to suss out a pattern that could shed at least a little light on the factors that put a person at higher risk of developing the condition. read more By Angus Liu After 50 years establishing itself as one of the largest pharma companies in China, Jiangsu Hengrui Pharmaceuticals is launching Luzsana Biotechnology for the global market. With a unique operating model, the subsidiary aims to “quantifiably reduce costs” of medicines, its CEO said, starting with a PD-1 cancer immunotherapy. read more By Annalee Armstrong “We just don’t have the studies” became a familiar refrain for Kirsten Bibbins-Domingo, M.D., Ph.D., chair of the Committee on Improving Representation of Women and Underrepresented Minorities in Clinical Trials and Research. A new report from the committee shines a light on the “critical shortcoming” in clinical research conducted in the U.S.: a lack of representation in clinical trials. read more By Paige Minemyer Humana's CenterWell and Welsh, Carson, Anderson and Stowe are teaming for a second joint venture focused on value-based primary care. read more By Andrea Park After proving that its blood test to measure the level of amyloid plaques in the brain matches up to the results of PET scans in predicting the onset of Alzheimer’s disease, C2N Diagnostics is expanding its slate of Alzheimer’s screening tools. read more By Ben Adams Danish pharma Novo Nordisk is running a new unbranded awareness campaign aimed at younger people struggling with obesity with a focus on not making them feel it is up to them alone to lose weight. read more By James Waldron,Annalee Armstrong Life sciences VC firm Flagship Pioneering has unveiled a new company called Sonata Therapeutics to develop cell signaling therapies for oncology, fibrosis, and autoimmune disorders. Flagship founded Sonata this year by combining two of the VC’s existing ventures: Inzen Therapeutics and Cygnal Therapeutics. read more By Angus Liu Roche and gene therapy rival bluebird bio are settling a short-lived trademark infringement lawsuit around the latter company's sickle cell disease awareness campaign. read more By Conor Hale The Inhance system previously received a green light for anatomic arthroplasty—where the implant mimics the shoulder’s natural ball-and-socket structure. Now it works both ways. read more By Dave Muoio Unveiled in 2020, the two New Jersey health systems' deal looks to form the state's first "premier academic medical center." read more | 